Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Biotechnology

Education

Appia Bio

Appia Bio's headquarters in Culver City, CA, United States

JJ Kang

Sylvaine Cases

Monica Jenkins

Tessa Aglupos-McCann

David Moskowitz

Jeff Wiezorek

Edmund Kim

Jason Damiano

Margo Roberts

Lili Yang

Francisco Gimenez

Pin Wang

Antoni Ribas

Irving Weissman

Daqing Cai

David Baltimore

Mitchell Kronenberg

Description

People (6)

Colin Flinders

Jiaji (Victor) Yu

Lanny Gov, Ph.D.

Maha Qubain

Samantha Bremner

Sean Allen

Jobs